Axogen, Inc. - Common Stock (AXGN)

Axogen Inc (AXGN) surpasses Q2 2025 estimates with strong revenue and EPS growth, raises full-year guidance, sparking a 15.8% pre-market stock surge.

The US market is yet to commence its session on Tuesday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.

Wondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements.

Let's delve into the US markets on Thursday and uncover the stocks that are experiencing notable gaps in today's session. Below, you'll find the gap up and gap down stocks.

AXGN stock results show that Axogen beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.

AXGN stock results show that Axogen beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.

Shares of SOPHiA GENETICS SA (NASDAQ: SOPH) fell sharply during Tuesday’s session after the company reported worse than expected fourth-quarter earnings and issued 2024 guidance.

AXGN stock results show that Axogen beat analyst estimates for earnings per share and beat on revenue for the fourth quarter of 2023.

Companies Reporting Before The Bell • NIO (NYSE:NIO) is estimated to report quarterly loss at $0.51 per share on revenue of $2.29 billion.

U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining around 50 points on Friday. The Dow traded up 0.13% to 37,490.36 while the NASDAQ rose 0.25% to 14,546.77. The S&P 500 also rose, gaining, 0.26% to 4,701.05.

Shares of Applied Therapeutics, Inc.

U.S. stocks traded higher, with the Dow Jones index gaining more than 100 points on Friday. Shares of The Greenbrier Companies, Inc. (NYSE: GBX) rose sharply during Friday’s session following upbeat earnings.